Wed, Feb 26, 9:36 PM (62 days ago)
**Certara, Inc. (CERT) 2024 10-K Summary:** Certara, Inc. reported total revenues of $385.1 million for the fiscal year ended December 31, 2024, reflecting a 9% increase from $354.3 million in 2023. The growth was driven by an 18% rise in software revenue, totaling $155.7 million, and a 3% increase in services revenue to $229.5 million. The net loss narrowed significantly to $12.1 million from a loss of $55.4 million in the previous year, attributed to increased revenues and lower operating expenses. Operating expenses totaled $232.4 million, down from $254.1 million, primarily due to a reduction in goodwill impairment charges. Earnings per share remained negative at $(0.08), but improved from $(0.35) in 2023. Certara's strategic focus on biosimulation technologies continues to enhance its market position, with a robust pipeline of acquisitions, including Chemaxon. The company maintains a strong balance sheet with cash and cash equivalents of $179.2 million and total debt of $298.5 million. Risks include reliance on key customers, regulatory changes, and competition in the biopharmaceutical market. Looking ahead, Certara aims to leverage AI advancements and expand its customer base while managing potential economic impacts on R&D spending.